Brenda J Chyla

9PUBLICATIONS
42CO-AUTHORS
Predictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 27, 2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.

|Feb 12, 2024
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.

Keith W Pratz, Brian A Jonas, Vinod Pullarkat

|Aug 25, 2022
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.

Daniel A Pollyea, Keith W Pratz, Andrew H Wei

|Jul 18, 2022
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia.

Naval Daver, Alexander E Perl, Joseph Maly

|Jan 22, 2022
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.

Marina Konopleva, Michael J Thirman, Keith W Pratz

|Jan 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations.

Daniel A Pollyea, Courtney D DiNardo, Martha L Arellano

Pageof 2

Frequent Collaborators

5 joint publications

Courtney D DiNardo

2 joint publications

Daniel A Pollyea

2 joint publications

Vinod Pullarkat

2 joint publications

Yinghui Duan